Welcome to the official website of Wuxi Changjiang Capsule Co., LTD.

Alibaba International

Analysis of foreign trade situation of medicine in the first quarter of 2011


In the first quarter of this year, the world economy continues to recover, the global pharmaceutical trade is heating up, the domestic pharmaceutical market is developing rapidly, and the import demand for high-end pharmaceutical products is growing significantly. China's pharmaceutical trade has achieved rapid growth in stages. The import and export value of pharmaceutical foreign trade reached 16.224 billion DOLLARS, with a year-on-year increase of 41.07%, among which, the export value was 10.119 billion dollars. Year-on-year growth of 38.13%, imports 6.105 billion US dollars, up 46.23% year on year, import and export growth were better than expected.

At present, the mid-range pharmaceutical products are still evident in the competitive advantage, and in the global pharmaceutical industry to developing countries in the process of further strengthening, in addition, our country medicine market to develop effective, booming exports to emerging pharmaceutical market, prompted China's pharmaceutical products export market space to further expand the original advantage.

one API products usher in a new stage of growth, with stable growth in developed markets and rapid development in emerging pharmaceutical markets
The expansion of global generic drug market demand and industrial transfer provide opportunities and space for China's API to further expand the international market. In the first quarter, China's API export reached $5.363 billion, with a year-on-year growth of 31.31%, realizing the largest quarterly year-on-year growth in API export since the financial crisis. In terms of market, exports to the European Union, the United States, Japan and other developed markets were stable and rising, with exports of us $1.414 billion, US $683 million and US $311 million, up 26.31%, 12.82% and 3.23% respectively, and the overall growth rate of the above three markets was 19.13%. Exports to India, ASEAN, Brazil and other major emerging pharmaceutical markets were $7.78, $5.03 and $158 million, up 39.15%, 45.64% and 55.82% respectively, and the proportion of the above three regions in total exports increased from 24.69% to 26.9%. The trade regions of emerging pharmaceutical markets are driving the export of apis more and more obviously. To become the most potential regional market. At the same time, statistics show that the overall export growth of API in the first quarter was mainly driven by the export quantity, which increased by 39.53% and the export price decreased by 5.89%, further indicating that the fierce domestic market competition pattern has not changed, and the phenomenon of price pressure is prominent. In terms of main varieties, the export growth of traditional bulk commodities was weak. The export volume of 10 key products, such as heparin sodium, vitamin C, vitamin E and penicillin industrial salt, increased by 7.23%, while the export price decreased by 16.51% and the export volume decreased by 10.48%. Basically, there were serious homogenized competition. On the other hand, the export of some apis, such as macrolides antibiotics, hormones, chloramphenicol and tetracycline, improved significantly, and their export prices increased, with average prices rising 30.39%, 19.84%, 31.24% and 40.05%, respectively. Exports increased by 100.35%, 23.69%, 60.72% and 37.1% respectively.

two The export of high-end pharmaceutical products is differentiated, the export growth of preparations is declining, and the export situation of diagnosis and treatment equipment is optimistic
In the first quarter, the export of high-end pharmaceutical products represented by western pharmaceutical preparations and diagnosis and treatment equipment appeared differentiation. Exports of western medicine preparations rose 23.71% in the first quarter, driven by strong exports from Astrazeneca. Export growth slowed from a year earlier. Joint ventures of astrazeneca pharmaceutical co., LTD., using the API industry strength, will production to China, formulation of new export $73.5 million in the first quarter, mostly exported to Australia, quickly become western medicine preparations export first, become the main driver of export growth in the first quarter preparations, astrazeneca new export factors neglected, Exports of pharmaceuticals rose only 2% in the first quarter, down nearly a third from the same period last year. State-owned and private enterprises still focus on Asia, Africa and South America, with less developed markets accounting for 80% of their exports. The high-end market is difficult to effectively open the mainstream market in Europe and The United States due to the high entry threshold, weak r&d strength of enterprises, few products with independent intellectual property rights, insufficient innovation capacity of generic drugs, and a large number of low-end products. The future development still has great uncertainty.
The export of medical equipment showed strong growth, with the export of 1.423 billion US dollars in the first quarter, up 52.82% year on year, accounting for 44.07% of the export of medical equipment. The export growth is manifested in two aspects. First, the proportion of high-end medical equipment increased, and the export market scope of mri devices, X-ray tomographic instruments, color ultrasonic diagnostic instruments and other products expanded, driving the export volume of high-end products increased, thus driving the overall average export price of medical equipment increased by 54.90%. Second, major export markets grew in an all-round way, emerging markets in particular developed rapidly. Exports to the European Union, the United States and Japan increased by 48.25%, 28.82% and 49.38% respectively. Asean, Middle East, Africa, India, Russia and other markets increased by 68.21%, 97.03%, 92.43%, 104.11%, 140.93%, respectively. The global market recognition of Chinese medical equipment is gradually increasing. In addition, the original leading position of foreign-funded products in the export of medical equipment has declined, and the proportion of state-owned private enterprises has increased significantly. In the first quarter, the proportion of foreign-funded enterprises in the export of medical equipment has decreased from 73.66% in the same period to 63.93%, and the proportion of state-owned private enterprises has increased by nearly 10 percentage points to 35.98%. In particular, the export growth rate of private enterprises reached 134.94%, but the low concentration and small export scale are still the main problems faced by state-owned and private enterprises.

3. The export prices of traditional medical dressings and disposable consumables rose sharply due to the rising prices of raw materials
In the first quarter, China's exports of traditional medical dressings and disposable consumables increased significantly, by 103.58% and 45.25% respectively, while the export volume did not change significantly. The main reason for the sharp increase in the export of medical dressings is that the export prices of cotton, gauze and bandage rose by 39.12%, cotton surgical towel rose by 46.71%, bleached and unbleached cotton medical gauze rose by 68.4% and 136.77%, respectively. Combined with global customs data (GTI) analysis, the first two months of this year, our cotton wound dressing product price surge has no obvious effects on the global market demand, China's medical dressing products in the European Union and north American market so, quantity and price continue to maintain steady growth, market share increase seven and 11% respectively, Reach 58.11% and 56.44%, still occupy the absolute market share, the competitive advantage is extremely obvious. However, it is worth noting that ASEAN, India, Mexico and other countries are gradually entering the Medical dressing market in Europe and the United States, especially for the EU market, the growth rate of Thailand and India respectively reached 176.08% and 60.95%, although the market share is less than 5%, but the competition situation has gradually emerged. Meanwhile, some former EU countries such as Britain, France and the Netherlands have gradually withdrawn from the medical dressing market.
Disposable consumables increased significantly in major global markets, 48.50% in Asia, 29.20% in THE European Union, 59.13% in North America, 33.42% in Africa, and 23.85% in average export prices.

Four. The domestic pharmaceutical market is developing rapidly, and the proportion of high-end products continues to increase
In the first quarter, China's drug import market continued to maintain a substantial growth, the import amount of 6.105 billion US dollars, with a year-on-year growth rate of 46.23%. Pharmaceutical imports showed the following characteristics: first, the concentration of source countries continued to increase, and drug imports from the European Union, the United States, Japan and other developed countries accounted for 75% of the total drug imports, with a total growth rate of 50.78%; Second, imports from India, Brazil and other countries with rapid development of pharmaceutical industry increased steadily, with an increase rate of 35.45% and 163.81% respectively. Western medicine raw materials and western patent medicines were the main imported varieties. Third, the proportion of high-end pharmaceutical products increased, which is embodied in the increase in the import price and proportion of Western patent medicine, while the proportion of API and equipment products decreased.
At present, China is entering an aging society, the domestic medical system is improving day by day, the domestic pharmaceutical market is expected to expand, the demand for foreign medicine will maintain a relatively rapid growth, but due to the gap between export and import is still large, the trade deficit will not be significantly reversed in the short term.

Five. Pharmaceutical exports in the second quarter will turn to moderate growth, year-on-year growth will decline
Due to changes in the global pharmaceutical industry pattern, the direction of the global pharmaceutical market is changing. In order to reduce costs, the global pharmaceutical production and research and development began to shift to developing countries including China, India, Israel and Brazil, and the proportion of global generic drug sales increased. In addition, the economic recovery in the developed countries and emerging medical market fast development, the global pharmaceutical market demand growth effectively, the above factors will continue to promote the steady growth of global pharmaceutical trade, at the same time our country active pharmaceutical ingredients, medical equipment product competitive advantage, make the joint venture pharmaceutical enterprises in our country further evolution of the space, will there be a substantial increase in imports and exports. In terms of export prices, as global inflation has not been effectively contained and pharmaceutical production costs in China have increased, it is an inevitable trend for export prices to gradually reflect the cost factor. Monthly data of some bulk API products have shown that export prices have begun to rise slowly. Therefore, in the medium and long term, there is still room for further expansion in market increment and export price of Chinese pharmaceutical products.
In terms of negative factors, due to the rapid growth of pharmaceutical export recently, some products, especially API products, will have periodic market surplus, which will inhibit the increase of export to a certain extent.

Combined with the above factors, it is expected that pharmaceutical exports in the second quarter will continue to remain optimistic, but the growth rate will decline.



3542 Zhencheng Road, Loess Town, Jiangyin City, Jiangsu Province

Mobile Phone Ali

Mobile phone Ali scan


Message feedback

Username used for comment:

All rights reserved@2021  Wuxi Changjiang Capsule Co. LTD  苏ICP备2021050454号-1  BY:xinnet